Table 3.
Comparison of survey and NCR data (10-year prevalence) for rare and common cancer patients
| Rare cancer | Common cancer | |||
|---|---|---|---|---|
| Survey | NCR | Survey | NCR | |
| Age in years, mean | 61 | 58 | 63 | 65 |
| Gender, % | ||||
| Male | 39% | 47% | 33% | 48% |
| Female | 61% | 53% | 67% | 52% |
| Type of cancer, % | ||||
| Sarcomas | 12% | 8% | 0% | 0% |
| Female genital organs and breast cancer | 15% | 20% | 43% | 26% |
| Male genital organ and urological cancer | 4% | 10% | 19% | 22% |
| Neuroendocrine tumors | 2% | 7% | 0% | 0% |
| Cancer of digestive tract | 15% | 6% | 19% | 17% |
| Cancer of endocrine organs | 5% | 5% | 0% | 0% |
| Cancer of head and neck | 8% | 16% | 0% | 0% |
| Thoracic cancer | 2% | 2% | 7% | 6% |
| Melanoma of skin and eye | 0% | 3% | 4% | 24% |
| Cancer of central nervous system | 3% | 5% | 0% | 0% |
| Hematological cancer | 37% | 18% | 9% | 7% |
| Number of (types of) treatmenta, % | ||||
| No treatment | 3% | 4% | 1% | 6% |
| 1 type of treatment | 31% | 46% | 25% | 40% |
| 2 types of treatment | 36% | 28% | 31% | 30% |
| > 2 types of treatment | 29% | 22% | 43% | 24% |
| Hospital of diagnosis, % | ||||
| Academic or cancer-specialized hospital | 27% | 17% | 13% | 8% |
| Top-clinical hospital | 45% | 48% | 48% | 51% |
| General hospital | 29% | 36% | 39% | 41% |
| Hospital of treatment, % | ||||
| Academic or cancer-specialized hospital | 56% | 43% | 25% | 12% |
| Top-clinical hospital | 30% | 37% | 45% | 51% |
| General hospital | 14% | 20% | 30% | 37% |
| Diagnosis and treatment in one hospital, % | ||||
| Yes | 33% | 51% | 42% | 64% |
| No | 67% | 49% | 59% | 36% |
| Number of hospitals patients were treated in, % | ||||
| 1 | 60% | 80% | 57% | 74% |
| ≥ 2 | 40% | 20% | 43% | 26% |
a Types of treatment include surgery, radiation, chemotherapy, hormonal therapy, targeted therapy, stem cell transplantation, active surveillance and wait-and-see